AstraZeneca highly values the discovery research and drug development activities being performed in Japan.
Through strategic alliances, licensing and R&D collaborations AstraZeneca in Japan contributes to develop innovative drugs and can thereby help improve people’s lives globally. Our representatives in Japan act as contacts for the following alliance activities, and we are also seeking in-licensing oppor-tunities (especially oncology) for the Japanese territory
Key areas of partnering interest
Pharmaceutical and Biotechnology companies
- Research collaborations for discovery
- Licensing compounds and products (global and/or Japan)
- Technology Transfer
Acmadeia
- Research collaborations for discovery
- Technology Transfer
Contact information
For your first contact, please send an e-mail to
biotech.transfer.japan@astrazeneca.com
Iku Sugioka, Licensing compounds and products
Masaki Nakanishi, Licensing compounds and products
Motonori Yamaguchi, Research collaborations and technology transfer
Akiko Hiraide, Research collaborations and technology transfer
E-mail:
firstname.lastname@astrazeneca.com
- Replace with authentic names
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 10:24 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
